Abstract:Dietary fibre regulates blood pressure (BP) through gut microbial production of acidic metabolites called short-chain fatty acids (SCFAs). The acidic environment in the large intestine activates a proton-sensing G-protein coupled receptor, GPR65. We aimed to characterize the luminal pH in the intestine of hypertensive patients and normotensive individuals, and to validate in a murine model that dietary fibre intake is a critical determinant for intestinal pH. Furthermore, we aimed to determine whether pH-sensing by GPR65 mediates the cardiovascular protection conferred by dietary fibre. 15 normotensive and 40 hypertensive (16 treated) participants had ambulatory BP profiles recorded using a Mobil-O-Graph device (CardioScan). Their intestinal luminal pH was measured in real-time by a SmartPillTM Motility Testing System (Medtronic). Analyses were performed on SPSS. Intestinal pH of C57BL/6J wild-type (WT) mice was measured after a 7-day dietary intervention of high-fibre (HF) or low-fibre (LF) diets (n = 5/group). Male WT and Gpr65-/- mice fed with HF or LF diets were implanted with minipumps containing angiotensin II (Ang-II, 0.5 mg/kg/day, 28 days, n = 11–12/group). BP was measured by tail-cuff, cardiac function by ultrasound, and fibrosis by Massons trichrome staining. Compared to normotensive individuals, hypertensive participants had higher colonic minimum pH (mean ± SEM: 5.03 ± 0.08 vs 5.22 ± 0.34, the beta coefficient = 2.98, P = 0.024 adjusted for age, sex, BMI), driven by changes in the transverse colon where dietary fibre is fermented. In our murine model, HF fed mice exhibited lower colonic pH compared to LF fed mice (HF vs LF, 6.03 ± 0.42 vs 7.58 ± 0.31, P < 0.001). This was abolished when mice were treated with antibiotics. Under HF diet, Ang-II treated Gpr65-/- mice had significantly higher BP (mean arterial pressure, WT vs Gpr65-/-, 90.7 ± 2.22 vs 101.3 ± 1.82mmHg, P = 0.022), heart to tibia length ratio (0.0096 ± 0.0004 vs 0.0112 ± 0.0018 g/mm, P = 0.036), left ventricle posterior wall in the diastole (0.831 ± 0.016 vs 0.966 ± 0.020 mm, P = 0.010), cardiac fibrosis (1.44 ± 0.15% vs 2.30 ± 0.09%, P = 0.026) and lower ejection fraction (65.65 ± 1.94% vs 54.65 ± 1.60%, P < 0.001) and fractional shortening (22.70 ± 1.52% vs 15.63 ± 0.69%, P < 0.001) than Ang-II treated WT mice. The cardiovascular impact of Gpr65 genotype when Ang-II mice were fed with LF diet was negligible (All P > 0.05). This is the first evidence hypertensive participants have a higher luminal pH in the colon. This likely results from the difference in dietary fibre intake, which in a murine model profoundly determined the colonic pH. Low pH activates GPR65 signalling, which underlies the cardiovascular protection by dietary fibre. Our findings demonstrate a novel mechanism for BP regulation.

Abstract P001: Repurposing A Drug Targeting Inflammatory Bowel Disease For Lowering Hypertension

PPAR beta/gamma mediates the antihypertensive activity of a synbiotic preparation of Bifidobacterium lactis and Lactobacillus acidophilus in spontaneous hypertensive rats

Intestinal microbiota by angiotensin receptor blocker therapy exerts protective effects against hypertensive damages

Differing contributions of the gut microbiota to the blood pressure lowering effects induced by first‐line antihypertensive drugs

Restructuring the Gut Microbiota by Intermittent Fasting Lowers Blood Pressure

Fecal Microbiota Transplantation Regulates Blood Pressure by Altering Gut Microbiota Composition and Intestinal Mucosal Barrier Function in Spontaneously Hypertensive Rats

Abstract P238: Bile Acid Metabolites Modulate Hypertension

Mycophenolate Improves Brain-Gut Axis Inducing Remodeling of Gut Microbiota in DOCA-Salt Hypertensive Rats

Mycophenolate mediated remodeling of gut microbiota and improvement of gut-brain axis in spontaneously hypertensive rats

Effects of Losartan, Atorvastatin, and Aspirin on Blood Pressure and Gut Microbiota in Spontaneously Hypertensive Rats

Reshaping commensal gut microbiota in early life lowers blood pressure potentially via a succinate mediated mechanism

The Role of Gut Microbiome in Mediating the Effect of Inflammatory Bowel Disease on Hypertension: a Two-Step, Two-Sample Mendelian Randomization Study

AW-NI-2: A HIGH-FIBRE DIET ATTENUATES HYPERTENSION BY IMPROVING GUT BARRIER INTEGRITY VIA SCFA-RECEPTOR SIGNALLING

Lactobacillus Induced by Irbesartan on Spontaneously Hypertensive Rat Contribute to Its Antihypertensive Effect.

PS-B11-9: LOW COLONIC PH AND PROTON-SENSOR GPR65: A MISSING BRIDGE LINKING DIET, GUT MICROBIOTA AND CARDIOVASCULAR HEALTH

Potassium Alginate Oligosaccharides Alter Gut Microbiota, and Have Potential to Prevent the Development of Hypertension and Heart Failure in Spontaneously Hypertensive Rats

Abstract P112: Elevated Blood Pressure In Conventionalized Germ-free Rats Is Coupled With Upregulation Of Kynurenic Pathway Metabolites And Central Immune Responses

Abstract MP38: Identification Of A Gut Microbe That Attenuates The Blood Pressure Lowering Effect Of ACEi Quinapril

Identification of a Gut Commensal That Compromises the Blood Pressure-Lowering Effect of Ester Angiotensin-Converting Enzyme Inhibitors

Engineered probiotics Clostridium butyricum‐pMTL007‐GLP‐1 improves blood pressure via producing GLP‐1 and modulating gut microbiota in spontaneous hypertension rat models

Critical Role of the Interaction Gut Microbiota – Sympathetic Nervous System in the Regulation of Blood Pressure